Sun Pharmaceutical Industries Ltd (SUNPHARMA) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{ "main_header": { "sid": 948699, "name": "Sun Pharma.Inds.", "stock_name": "Sun Pharma.Inds.", "full_name": "Sun Pharmaceutical Industries Ltd", "name_url": "stocks-analysis/sun-pharmainds", "exchange": 1, "exchangecode": "", "primexch": 1, "country_id": 34, "currency": "INR", "cmp": "1,693.60", "chg": -34.9, "chgp": "-2.02%", "dir": -1, "prev_price": "1,728.50", "mcapval": "397,174.00 Cr", "mcap": "Large Cap", "scripcode": 524715, "symbol": "SUNPHARMA", "ind_name": "Pharmaceuticals & Biotechnology", "ind_code": 4, "indexname": "India SENSEX", "isin": "INE044A01036", "curr_date": "Apr 02", "curr_time": "", "bse_nse_vol": "40.65 lacs", "exc_status": "Active", "traded_date": "Apr 02, 2026", "traded_date_str": "2026 04 02", "score": "", "scoreText": "", "Live": 0, "market_time": 0, "is_blur": 1, "is_blur_class": "blur-registerF-score-header", "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/sun-pharmainds-948699-1&utm_source=Spage_Header_Score", "mojoone": { "ismore": 0, "all_data": [] } }, "news": { "results": [ { "title": "1,509 Call Contracts Traded on Sun Pharmaceutical Industries Ltd as Stock Declines Amid Heavy Options Activity", "link": "https://www.marketsmojo.com/news/stocks-in-action/sun-pharmaceutical-sees-heavy-call-option-activity-amid-recent-price-weakness-3930029", "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/SunPharmaceutic_most_active_stocks_calls_3930029.png", "date": "2026-04-02 10:00:15", "description": "On 2 Apr 2026, 1,509 call contracts at the Rs 1,660 strike price changed hands on Sun Pharmaceutical Industries Ltd, with the stock closing marginally above this level at Rs 1,661.40 despite a 4.35% decline on the day. This juxtaposition of heavy call activity and falling stock price raises questions about the underlying directional sentiment in the options market." }, { "title": "Rs 1,500 Puts — 9.7% Below Current Price — Draw 1,302 Contracts on Sun Pharmaceutical Industries Ltd", "link": "https://www.marketsmojo.com/news/stocks-in-action/sun-pharmaceutical-sees-heavy-put-option-activity-amid-bearish-sentiment-3930030", "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/SunPharmaceutic_most_active_stocks_puts_3930030.png", "date": "2026-04-02 10:00:14", "description": "The stock is down 4.35% today and has fallen over 8% in the last four sessions, while 1,302 put contracts at the Rs 1,500 strike traded on 2 April 2026. For Sun Pharmaceutical Industries Ltd, this put activity suggests a directional bearish stance rather than mere protection." }, { "title": "Sun Pharmaceutical Industries Ltd Opens 3.67% Lower as Technicals Signal Continued Pressure", "link": "https://www.marketsmojo.com/news/stocks-in-action/sun-pharmaceutical-industries-ltd-opens-with-weak-start-significant-gap-down-amid-market-concerns-3929858", "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/SunPharmaceutic_gapdown_3929858.png", "date": "2026-04-02 09:35:56", "description": "" }, { "title": "Sun Pharmaceutical Industries Ltd Hits Intraday Low Amid Price Pressure", "link": "https://www.marketsmojo.com/news/stocks-in-action/sun-pharmaceutical-industries-ltd-hits-intraday-low-amid-price-pressure-3929823", "imagepath": "https://i.marketsmojo.com/newsimg/2026/4/SunPharmaceutic_priceRelatedfactors_3929823.png", "date": "2026-04-02 09:32:30", "description": "Sun Pharmaceutical Industries Ltd experienced a notable decline today, hitting an intraday low of Rs 1,635.05, reflecting a 5.4% drop as the stock faced significant price pressure amid broader market weakness and sector underperformance." }, { "title": "P/E at 34.72 vs Industry's 31.34: What the Data Shows for Sun Pharmaceutical Industries Ltd", "link": "https://www.marketsmojo.com/news/stocks-in-action/sun-pharmaceutical-industries-ltd-navigating-market-pressures-amidst-nifty-50-membership-3929785", "imagepath": "", "date": "2026-04-02 09:21:33", "description": " <div class=\"article-news-new\">\n <div class=\"article-container\">\n\n<div class=\"article-content\">\n <p><strong>Valuation Picture: Premium Amidst Sector Norms</strong></p>\n <p>The current P/E ratio of <a href=\"https://www.marketsmojo.com/stocks-analysis/sun-pharma.inds.-948699-0\" class=\"stk\">Sun Pharmaceutical Industries Ltd</a> at 34.72 stands approximately 10.8% above the industry average of 31.34. This premium suggests that investors are willing to pay more for each rupee of earnings relative to its peers in the Pharmaceuticals & Biotechnology sector. Such a valuation gap often reflects expectations of superior earnings quality, growth prospects, or market positioning. However, the premium is not excessive compared to some high-growth pharma peers, indicating a balanced valuation stance. The question remains — <a href=\"https://www.marketsmojo.com/stocks-analysis/sun-ph..." }, { "title": "P/E at 34.72 vs Industry's 31.39: What the Data Shows for Sun Pharmaceutical Industries Ltd", "link": "https://www.marketsmojo.com/news/stocks-in-action/sun-pharmaceutical-industries-ltd-nifty-50-membership-reinforces-market-standing-amid-institutional-shifts-3927724", "imagepath": "", "date": "2026-04-01 09:26:04", "description": " <div class=\"article-news-new\">\n <div class=\"article-container\">\n\n<div class=\"article-content\">\n <p><strong>Valuation Picture: Premium Amidst Sector Norms</strong></p>\n <p>The stock’s P/E ratio of 34.72 stands approximately 10.6% above the industry average of 31.39, signalling a valuation premium that investors are currently willing to pay for <a href=\"https://www.marketsmojo.com/stocks-analysis/sun-pharma.inds.-948699-0\" class=\"stk\">Sun Pharmaceutical Industries Ltd</a>. This premium suggests expectations of relatively stronger earnings growth or superior business fundamentals compared to peers. However, the premium is not excessively stretched, indicating a balanced market view rather than exuberance. The sector’s P/E itself reflects the pharmaceutical industry’s growth prospects and risk profile, with the company’s valuation aligning with its large-cap status and m..." }, { "title": "P/E at 35.45 vs Industry's 31.90: What the Data Shows for Sun Pharmaceutical Industries Ltd", "link": "https://www.marketsmojo.com/news/stocks-in-action/sun-pharmaceutical-industries-ltd-navigating-nifty-50-membership-and-institutional-dynamics-3923598", "imagepath": "", "date": "2026-03-30 09:26:00", "description": " <div class=\"article-news-new\">\n <div class=\"article-container\">\n\n<div class=\"article-content\">\n <p><strong>Valuation Picture: Premium Reflecting Market Confidence?</strong></p>\n <p>The current P/E ratio of <a href=\"https://www.marketsmojo.com/stocks-analysis/sun-pharma.inds.-948699-0\" class=\"stk\">Sun Pharmaceutical Industries Ltd</a> at 35.45 stands noticeably above the sector average of 31.90. This premium suggests that investors are willing to pay more for each rupee of earnings compared to the broader Pharmaceuticals & Biotechnology industry. Such a valuation gap often implies expectations of superior earnings growth or a perception of stronger fundamentals relative to peers. However, it also raises questions about whether the premium is justified given the company’s recent performance trends — <a href=\"https://www.marketsmojo.com/stocks-analysis/sun-pharma.in..." }, { "title": "Sun Pharmaceutical Industries Ltd is Rated Buy", "link": "https://www.marketsmojo.com/news/stock-recommendation/sun-pharmaceutical-industries-ltd-is-rated-buy-3922751", "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/SunPharmaceutic_mojoScore_3922751.png", "date": "2026-03-29 10:10:26", "description": "Sun Pharmaceutical Industries Ltd is rated 'Buy' by MarketsMOJO, with this rating last updated on 23 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 29 March 2026, providing investors with the latest insights into the company’s performance and outlook." }, { "title": "Sun Pharmaceutical Gains 1.02%: 5 Key Factors Driving the Week’s Momentum", "link": "https://www.marketsmojo.com/news/stocks-in-action/sun-pharmaceutical-gains-102-5-key-factors-driving-the-weeks-momentum-3921809", "imagepath": "", "date": "2026-03-28 13:05:12", "description": " <div class=\"article-news-new\">\n <div class=\"article-container\">\n\n<div class=\"article-content\">\n <div class=\"highlight-box\">\n <h3>Key Events This Week</h3>\n <p><strong>23 Mar:</strong> Stock declined 1.19% amid broad market sell-off</p>\n <p><strong>24 Mar:</strong> Significant open interest surge despite slight price dip</p>\n <p><strong>25 Mar:</strong> Intraday high reached with 3.08% surge and strong derivatives activity</p>\n <p><strong>27 Mar:</strong> Call option activity peaks ahead of expiry; price closes near 52-week high</p>\n </div>\n\n <div class=\"stats-row\">\n <div class=\"stat-item\"><div class=\"stat-label\">Week Open</div><div class=\"stat-value\">Rs.1,777.45</div></div>\n <div class=\"stat-item\"><div class=\"stat-label\">..." } ], "total": 1038, "sid": "948699", "stock_news_url": "https://www.marketsmojo.com/news/sun-pharmaceutical-industries-948699" }, "announcements": [ { "details": "Sun Pharmaceutical Industries Limited has informed the Exchange regarding Intimation under Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015", "source": "NSE", "caption": "Sun Pharmaceutical Industries Limited - Other General Purpose", "datetime": "09-Dec-2019" }, { "details": "Sun Pharmaceutical Industries Limited has informed the Exchange regarding a press release dated November 06, 2019, titled \"Sun Pharma and AstraZeneca enter into License Agreement for Novel Oncology products in China\".", "source": "NSE", "caption": "Sun Pharmaceutical Industries Limited - Press Release", "datetime": "06-Nov-2019" }, { "details": "Sun Pharmaceutical Industries Limited has informed the Exchange regarding 'Please find enclosed Compliance Certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018'.", "source": "NSE", "caption": "Sun Pharmaceutical Industries Limited - Updates", "datetime": "18-Oct-2019" } ], "corporate_actions": [ { "img": "board-meeting.svg", "title": "BOARD MEETING", "msg": "<span>No</span> Upcoming Board Meetings", "data": [] }, { "img": "dividend.svg", "title": "DIVIDEND", "msg": "", "data": [ { "txt": "Sun Pharmaceutical Industries Ltd has declared <strong>1100%</strong> dividend, ex-date: 05 Feb 26", "dt": "2026-02-05", "middle_text": "Dividend Alert" } ] }, { "img": "splits.svg", "title": "SPLITS", "msg": "", "data": [ { "txt": "Sun Pharmaceutical Industries Ltd has announced <strong>1:5</strong> stock split, ex-date: 25 Nov 10", "dt": "2010-11-25", "middle_text": "Split" } ] }, { "img": "bonus.svg", "title": "BONUS", "msg": "", "data": [ { "txt": "Sun Pharmaceutical Industries Ltd has announced <strong>1:1</strong> bonus issue, ex-date: 29 Jul 13", "dt": "2013-07-29", "middle_text": "Bonus Alert" } ] }, { "img": "rights-issues.svg", "title": "RIGHTS", "msg": "No <strong>Rights</strong> history available", "data": [] } ] }

Valuation Picture: Premium Amidst Sector Norms

The current P/E ratio of Sun Pharmaceutical Industries Ltd at 34.72 stands approximately 10.8% above the industry average of 31.34. This premium suggests that investors are willing to pay more for each rupee of earnings relative to its peers in the Pharmaceuticals & Biotechnology sector. Such a valuation gap often reflects expectations of superior earnings quality, growth prospects, or market positioning. However, the premium is not excessive compared to some high-growth pharma peers, indicating a balanced valuation stance. The question remains — Read full news article

P/E at 34.72 vs Industry's 31.39: What the Data Shows for Sun Pharmaceutical Industries Ltd

2026-04-01 09:26:04

Valuation Picture: Premium Amidst Sector Norms

The stock’s P/E ratio of 34.72 stands approximately 10.6% above the industry average of 31.39, signalling a valuation premium that investors are currently willing to pay for Sun Pharmaceutical Industries Ltd. This premium suggests expectations of relatively stronger earnings growth or superior business fundamentals compared to peers. However, the premium is not excessively stretched, indicating a balanced market view rather than exuberance. The sector’s P/E itself reflects the pharmaceutical industry’s growth prospects and risk profile, with the company’s valuation aligning with its large-cap status and m...

Read full news article

P/E at 35.45 vs Industry's 31.90: What the Data Shows for Sun Pharmaceutical Industries Ltd

2026-03-30 09:26:00

Valuation Picture: Premium Reflecting Market Confidence?

The current P/E ratio of Sun Pharmaceutical Industries Ltd at 35.45 stands noticeably above the sector average of 31.90. This premium suggests that investors are willing to pay more for each rupee of earnings compared to the broader Pharmaceuticals & Biotechnology industry. Such a valuation gap often implies expectations of superior earnings growth or a perception of stronger fundamentals relative to peers. However, it also raises questions about whether the premium is justified given the company’s recent performance trends — Read full news article

Sun Pharmaceutical Industries Ltd is Rated Buy

2026-03-29 10:10:26

Sun Pharmaceutical Industries Ltd is rated 'Buy' by MarketsMOJO, with this rating last updated on 23 February 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 29 March 2026, providing investors with the latest insights into the company’s performance and outlook.